View Financial HealthPharmaron Beijing 配当と自社株買い配当金 基準チェック /16Pharmaron Beijing配当を支払う会社であり、現在の利回りは0.96%で、収益によって十分にカバーされています。主要情報1.0%配当利回り-0.05%バイバック利回り総株主利回り0.9%将来の配当利回り1.1%配当成長27.8%次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向24%最近の配当と自社株買いの更新お知らせ • Jun 20Pharmaron Beijing Co., Ltd. Approves Final Ordinary Dividend for Year Ended December 31, 2024, Payment Date Is 06 August 2025Pharmaron Beijing Co., Ltd. approved final ordinary dividend in cash for the year ended December 31, 2024 of RMB 2 per 10 share. Ex-dividend date is 04 July 2025 . Record date is 14 July 2025. Payment date is 06 August 2025. Date of shareholders' approval is 20 June 2025.お知らせ • Mar 26Pharmaron Beijing Co., Ltd. Proposes Final Dividend for the Financial Year Ended December 31, 2024Pharmaron Beijing Co., Ltd. proposed final dividend of RMB 2 per 10 shares for the financial year ended December 31, 2024.お知らせ • Jun 21Pharmaron Beijing Co., Ltd. Announces Final Cash Dividend on A Shares for the Year 2023, Payable June 27, 2024Pharmaron Beijing Co., Ltd. announced final cash dividend/10 shares (tax included) of CNY 2.00000000 on A shares for the year 2023. Record date is June 26, 2024. Ex-date is June 27, 2023. Payment date is June 27, 2024.お知らせ • Jun 08Pharmaron Beijing Co., Ltd. Approves Final Dividend for the Financial Year Ended December 31, 2023, Payable on July 26, 2024Pharmaron Beijing Co., Ltd. approved final dividend of RMB 2 per 10 shares for the financial year ended December 31, 2023. Ex-dividend date is on 27 June 2024. Record date is on 08 July 2024. Payment date is on 26 July 2024. Date of shareholders' approval is on 6 June 2024.お知らせ • Apr 26+ 1 more updatePharmaron Beijing Co., Ltd. (SZSE:300759) announces an Equity Buyback for CNY 300 million worth of its shares.Pharmaron Beijing Co., Ltd. (SZSE:300759) announces a share repurchase program. Under the program, the company will repurchase up to CNY 300 million worth of class A shares. The shares will be repurchased at a price of not more than CNY 31 per share. The A Shares repurchased will all be cancelled and the Company’s registered capital will be reduced accordingly. The purpose of the program is to enhance investor’s confidence, and comprehensively taking into account the Company’s financial conditions, future development and reasonable valuation levels. The program will be funded out of the company's own funds. The program will be valid till 3 months.お知らせ • Mar 27Pharmaron Beijing Co., Ltd. Proposes Final Dividend for the Financial Year Ended December 31, 2023Pharmaron Beijing Co., Ltd. proposed final dividend of RMB 2 per 10 shares for the financial year ended December 31, 2023.すべての更新を表示Recent updatesお知らせ • May 22Pharmaron Beijing Co., Ltd., Annual General Meeting, Jun 12, 2026Pharmaron Beijing Co., Ltd., Annual General Meeting, Jun 12, 2026, at 13:30 China Standard Time. Location: juhui hall, 5/floor, block b, zhaolin plaza, no. 19 ronghua middle road, beijing economic & technological development area, daxing district, beijing., Chinaお知らせ • Apr 30Pharmaron Beijing Co., Ltd. Approves Changes in the Company's Accounting PoliciesThe board of directors of Pharmaron Beijing Co., Ltd. that the Board has resolved and approved the proposed changes in the Company's accounting policies. This announcement is made pursuant to the requirements of Rule 13.09(2) of the Listing Rules and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Cap. 571). On April 28, 2026, the audit committee of the Board (the "Audit Committee") reviewed and approved the Changes in Accounting Policies, the details of which are as follows: Overview of Changes in Accounting Policies (i) Nature, reasons and effective date of the Changes in Accounting Policies In December, 2025, the Ministry of Finance issued the Notice on the Issuance of Interpretation No. 19 of Accounting Standards for Business Enterprises (Cai Kuai [2025] No. 32) (hereinafter referred to as "Interpretation No. 19"), which stipulates the accounting treatments regarding (i) accounting treatment of indemnification assets in business combinations under non-common control, (ii) accounting treatment of disposing of capital reserve related to the acquisition of subsidiaries through business combinations under common control, (iii) derecognition of financial liabilities settled through electronic payment systems, (iv) assessment of contractual cash flow characteristics of financial assets and related disclosures, and (v) disclosures of equity instruments designated as measured at fair value through other comprehensive income. The Interpretation No. 19 shall take effect from January 1, 2026. In accordance with the Interpretation No. 19, the Company has adopted the above accounting standards for business enterprises and the related accounting policies commencing from the effective date specified therein. These Changes in Accounting Policies are made in accordance with the requirements of the unified national accounting system. (ii) Accounting policies adopted prior to the Changes in Accounting Policies Prior to the Changes in Accounting Policies, the Company adopted the Accounting Standards for Business Enterprises Basic Standards and various specific accounting standards, Application Guidelines for Accounting Standards for Business Enterprises, the interpretation announcements of the Accounting Standards for Business Enterprises and other relevant regulations issued by the Ministry of Finance. (iii) Accounting policies adopted after the Changes in Accounting Policies After the Changes in Accounting Policies, the Company will adopt the requirements of Interpretation No. 19. The unchanged remaining parts will continue to follow the Accounting Standards for Business Enterprises Basic Standards and various specific accounting standards, the Application Guidelines for Accounting Standards for Business Enterprises, the interpretation announcements of the Accounting Standards for Business Enterprises and other relevant regulations previously issued by the Ministry of Finance. II. Impacts of Changes in Accounting Policies on the Company These Changes in Accounting Policies are made by the Company in accordance with the relevant regulations and requirements of the Ministry of Finance, and are in compliance with relevant laws and regulations. The revised accounting policies objectively and fairly reflect the Company's financial position and operating results. The Changes in Accounting Policies do not involve retroactive adjustment of financial data for previous years, will have no material effect on the Company's financial position, operating results or cash flows, and do not prejudice the interests of the Company and all of its shareholders. The Change in Accounting Policies is a modification under the China Accounting Standards, and will not have any impact on the Company's audited consolidated financial statements prepared in accordance with IFRS Accounting Standards (which include all International Financial Reporting Standards, International Accounting Standards and Interpretations) as issued by the International Accounting Standards Board. III. Opinion of the Audit Committee of the Board The Audit Committee is of the opinion that the Changes in Accounting Policies are made by the Company in compliance with the requirements of the relevant documents issued by the Ministry of Finance and constitute changes in accounting policies as required by the unified national accounting system. The revised accounting policies objectively and fairly reflect the Company's financial position and operating results. The Changes in Accounting Policies do not involve retroactive adjustment of financial data for previous years and do not prejudice the interests of the Company and all of its shareholders. The Audit Committee unanimously approved the Changes in Accounting Policies. In accordance with the Rules Governing the Listing of Stocks on the ChiNext Board of the Shenzhen Stock Exchange and other applicable laws, regulations and departmental rules, the Changes in Accounting Policies are not required to be submitted to the Board or the 2025 AGM for approval.お知らせ • Apr 29Pharmaron Beijing Co., Ltd. Announces Board ResignationsPharmaron Beijing Co., Ltd. announced that Mr. LI Jiaqing and Mr. YU Jian will not stand for re-election of the fourth session of the Board. Each of Mr. LI Jiaqing and Mr. YU Jian has confirmed that he has no disagreement with the Board and there is no matter that need to be brought to the attention of the Shareholders with regard to his resignation. As at the date of this announcement, neither Mr. LI Jiaqing nor Mr. YU Jian has any interest in the shares of the Company within the meaning of Part XV of the SFO nor any other matter which needs to be brought to the attention of the Shareholders. The Board would like to take this opportunity to express its appreciation and gratitude to Mr. LI Jiaqing and Mr. YU Jian for their valuable contribution made to the Company during their respective term of service.お知らせ • Mar 31Pharmaron Beijing Co., Ltd. to Report Q1, 2026 Results on Apr 29, 2026Pharmaron Beijing Co., Ltd. announced that they will report Q1, 2026 results on Apr 29, 2026お知らせ • Jan 22Pharmaron Beijing Co., Ltd. has completed a Follow-on Equity Offering in the amount of HKD 1.333618 billion.Pharmaron Beijing Co., Ltd. has completed a Follow-on Equity Offering in the amount of HKD 1.333618 billion. Security Name: H shares Security Type: Common Stock Securities Offered: 58,440,762 Price\Range: HKD 22.82 Transaction Features: Subsequent Direct Listingお知らせ • Jan 15Pharmaron Beijing Co., Ltd. has filed a Follow-on Equity Offering in the amount of HKD 1.333618 billion.Pharmaron Beijing Co., Ltd. has filed a Follow-on Equity Offering in the amount of HKD 1.333618 billion. Security Name: H shares Security Type: Common Stock Securities Offered: 58,440,762 Price\Range: HKD 22.82 Transaction Features: Subsequent Direct Listingお知らせ • Jan 14Pharmaron Beijing Co., Ltd. Provides Earnings Guidance for the Financial Year Ended December 31, 2025Pharmaron Beijing Co., Ltd. provided earnings guidance for the financial year ended December 31, 2025. For the period, the company expects the revenue in the range of RMB 13,871.6256 million to RMB 14,239.8989 million, growth compared with the same period of last year is 13% - 16%. Net profit attributable to owners of the parent is expected to be in the range of RMB 1,614.0157 million to RMB 1,685.7498 million, decrease compared with the same period of last year of 6% to 10%. Basic earnings per share is expected to be in the range of RMB 0.0.9160 to RMB 0.9567.お知らせ • Dec 31Pharmaron Beijing Co., Ltd. to Report Fiscal Year 2025 Results on Mar 31, 2026Pharmaron Beijing Co., Ltd. announced that they will report fiscal year 2025 results on Mar 31, 2026お知らせ • Oct 29Pharmaron Beijing Co., Ltd. (SZSE:300759) entered into a definitive Share Purchase Agreement to acquire 82.54% stake in Wuxi Biortus Biosciences Co. Ltd.Pharmaron Beijing Co., Ltd. (SZSE:300759) entered into a definitive Share Purchase Agreement to acquire 82.54% stake in Wuxi Biortus Biosciences Co. Ltd. on October 28, 2025. With this transaction, it will further enhance its service capabilities in protein science, biological assaying and compound screening, protein crystallization and structure analysis and structure-based drug design. The transaction is expected to close upon the satisfaction of customary closing conditions.お知らせ • Sep 30Pharmaron Beijing Co., Ltd. to Report Q3, 2025 Results on Oct 29, 2025Pharmaron Beijing Co., Ltd. announced that they will report Q3, 2025 results on Oct 29, 2025お知らせ • Jul 02Pharmaron Beijing Co., Ltd. to Report First Half, 2025 Results on Aug 22, 2025Pharmaron Beijing Co., Ltd. announced that they will report first half, 2025 results on Aug 22, 2025お知らせ • Jun 20Pharmaron Beijing Co., Ltd. Approves Final Ordinary Dividend for Year Ended December 31, 2024, Payment Date Is 06 August 2025Pharmaron Beijing Co., Ltd. approved final ordinary dividend in cash for the year ended December 31, 2024 of RMB 2 per 10 share. Ex-dividend date is 04 July 2025 . Record date is 14 July 2025. Payment date is 06 August 2025. Date of shareholders' approval is 20 June 2025.お知らせ • May 29Pharmaron Beijing Co., Ltd., Annual General Meeting, Jun 20, 2025Pharmaron Beijing Co., Ltd., Annual General Meeting, Jun 20, 2025, at 13:30 China Standard Time. Location: no. 1 meeting room,4th floor, grand skylight international hotel beijing, building 10, avic plaza, no. 15 ronghua south road, yizhuang economic and technological development, zone, daxing Chinaお知らせ • Apr 28Pharmaron Beijing Co., Ltd. Announces Resignation of Hu Baifeng as Non-Executive Director and A Member of the Strategy CommitteePharmaron Beijing Co., Ltd. announced that Mr. Hu Baifeng (Mr. Hu) has tendered a voluntary resignation from his position as a non-executive Director of the Company and a member of the strategy committee of the Board (the Strategy Committee). Following Mr. Hu's resignation, he has voluntarily agreed to continue to perform his duties as a non-executive Director and a member of the Strategy Committee until the proposed election of the new non-executive Director is resolved by the shareholders of the Company (the Shareholders) at the upcoming annual general meeting of the Company for the year 2024 (the 2024 AGM).お知らせ • Mar 31Pharmaron Beijing Co., Ltd. to Report Q1, 2025 Results on Apr 28, 2025Pharmaron Beijing Co., Ltd. announced that they will report Q1, 2025 results on Apr 28, 2025お知らせ • Mar 26Pharmaron Beijing Co., Ltd. Proposes Final Dividend for the Financial Year Ended December 31, 2024Pharmaron Beijing Co., Ltd. proposed final dividend of RMB 2 per 10 shares for the financial year ended December 31, 2024.お知らせ • Dec 31Pharmaron Beijing Co., Ltd. to Report Fiscal Year 2024 Results on Mar 27, 2025Pharmaron Beijing Co., Ltd. announced that they will report fiscal year 2024 results on Mar 27, 2025お知らせ • Sep 30Pharmaron Beijing Co., Ltd. to Report Q3, 2024 Results on Oct 30, 2024Pharmaron Beijing Co., Ltd. announced that they will report Q3, 2024 results on Oct 30, 2024お知らせ • Jun 29Pharmaron Beijing Co., Ltd. to Report First Half, 2024 Results on Aug 28, 2024Pharmaron Beijing Co., Ltd. announced that they will report first half, 2024 results on Aug 28, 2024お知らせ • Jun 22Johnson & Johnson (NYSE:JNJ) completed the acquisition of Proteologix, Inc. from Pharmaron Beijing Co., Ltd and other shareholders for approximately $850 million.Johnson & Johnson (NYSE:JNJ) entered into a definitive agreement to acquire Proteologix, Inc. from Pharmaron Beijing Co., Ltd and other shareholders for approximately $850 million and with potential for an additional milestone payment. on May 16, 2024. The transaction is subject to antitrust clearance and other customary closing conditions. The transaction is expected to close mid-year 2024. Centerview Partners LLC served as exclusive financial advisor, and Goodwin Procter as legal counsel to Proteologix on the transaction. The transaction has been approved by Pharmaron Beijing Co., Ltd's board.As of year ended 2023, Proteologix, Inc reported total assets of $31.04 million, total common equity of $30.73 million, EBIT of $5.74 million and net income of $5.74 million. Janet Xiao of Morrison & Foerster LLP acted as legal advisor to Proteologix, Inc.Johnson & Johnson (NYSE:JNJ) completed the acquisition of Proteologix, Inc. from Pharmaron Beijing Co., Ltd and other shareholders on June 21, 2024.お知らせ • Jun 21Pharmaron Beijing Co., Ltd. Announces Final Cash Dividend on A Shares for the Year 2023, Payable June 27, 2024Pharmaron Beijing Co., Ltd. announced final cash dividend/10 shares (tax included) of CNY 2.00000000 on A shares for the year 2023. Record date is June 26, 2024. Ex-date is June 27, 2023. Payment date is June 27, 2024.お知らせ • Jun 08Pharmaron Beijing Co., Ltd. Approves Final Dividend for the Financial Year Ended December 31, 2023, Payable on July 26, 2024Pharmaron Beijing Co., Ltd. approved final dividend of RMB 2 per 10 shares for the financial year ended December 31, 2023. Ex-dividend date is on 27 June 2024. Record date is on 08 July 2024. Payment date is on 26 July 2024. Date of shareholders' approval is on 6 June 2024.お知らせ • May 16Pharmaron Beijing Co., Ltd., Annual General Meeting, Jun 06, 2024Pharmaron Beijing Co., Ltd., Annual General Meeting, Jun 06, 2024, at 13:30 China Standard Time. Location: paris hall, 3/f, pullman beijing south, no. 12 ronghua south road, beijing economic and technological development, area, daxing district, beijing Chinaお知らせ • Apr 26+ 1 more updatePharmaron Beijing Co., Ltd. (SZSE:300759) announces an Equity Buyback for CNY 300 million worth of its shares.Pharmaron Beijing Co., Ltd. (SZSE:300759) announces a share repurchase program. Under the program, the company will repurchase up to CNY 300 million worth of class A shares. The shares will be repurchased at a price of not more than CNY 31 per share. The A Shares repurchased will all be cancelled and the Company’s registered capital will be reduced accordingly. The purpose of the program is to enhance investor’s confidence, and comprehensively taking into account the Company’s financial conditions, future development and reasonable valuation levels. The program will be funded out of the company's own funds. The program will be valid till 3 months.お知らせ • Mar 30Pharmaron Beijing Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024Pharmaron Beijing Co., Ltd. announced that they will report Q1, 2024 results on Apr 26, 2024お知らせ • Mar 27Pharmaron Beijing Co., Ltd. Proposes Final Dividend for the Financial Year Ended December 31, 2023Pharmaron Beijing Co., Ltd. proposed final dividend of RMB 2 per 10 shares for the financial year ended December 31, 2023.お知らせ • Jan 29Pharmaron Beijing Co., Ltd. Provides Earnings Guidance for the Financial Year Ended December 31, 2023Pharmaron Beijing Co., Ltd. provided earnings guidance for the financial year ended December 31, 2023. For the period, the company expects the revenue in the range of RMB 11,395.5799 million to RMB 11,703.5685 million. Growth compared with the same period of last year is 11% - 14%. Net profit attributable to owners of the parent is expected to be in the range of RMB 1,567.0488 million to RMB 1,635.7790 million. Growth compared with the same period of last year of 14% to 19%. Basic earnings per share is expected to be in the range of RMB 0.8841 to 0.9229.お知らせ • Dec 29Pharmaron Beijing Co., Ltd. to Report Fiscal Year 2023 Results on Mar 28, 2024Pharmaron Beijing Co., Ltd. announced that they will report fiscal year 2023 results on Mar 28, 2024決済の安定と成長配当データの取得安定した配当: 配当金の支払いは安定していますが、 PHBB.Fが配当金を支払っている期間は 10 年未満です。増加する配当: PHBB.Fの配当金は増加していますが、同社は5年間しか配当金を支払っていません。配当利回り対市場Pharmaron Beijing 配当利回り対市場PHBB.F 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (PHBB.F)1.0%市場下位25% (US)1.4%市場トップ25% (US)4.2%業界平均 (Life Sciences)0.7%アナリスト予想 (PHBB.F) (最長3年)1.1%注目すべき配当: PHBB.Fの配当金 ( 0.96% ) はUS市場の配当金支払者の下位 25% ( 1.41% ) と比べると目立ったものではありません。高配当: PHBB.Fの配当金 ( 0.96% ) はUS市場の配当金支払者の上位 25% ( 4.2% ) と比較すると低いです。株主への利益配当収益カバレッジ: PHBB.Fは低い 配当性向 ( 23.9% ) であるため、配当金の支払いは利益によって十分にカバーされます。株主配当金キャッシュフローカバレッジ: PHBB.Fは高い 現金配当性向 ( 91.2% ) のため、配当金の支払いはキャッシュフローで十分にカバーされていません。高配当企業の発掘7D1Y7D1Y7D1YUS 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2024/08/11 16:04終値2024/05/14 00:00収益2024/03/31年間収益2023/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Pharmaron Beijing Co., Ltd. 16 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。24 アナリスト機関Bo LiBofA Global ResearchPei ChengChina Galaxy Securities Co., Ltd.Jin ZhangChina International Capital Corporation Limited21 その他のアナリストを表示
お知らせ • Jun 20Pharmaron Beijing Co., Ltd. Approves Final Ordinary Dividend for Year Ended December 31, 2024, Payment Date Is 06 August 2025Pharmaron Beijing Co., Ltd. approved final ordinary dividend in cash for the year ended December 31, 2024 of RMB 2 per 10 share. Ex-dividend date is 04 July 2025 . Record date is 14 July 2025. Payment date is 06 August 2025. Date of shareholders' approval is 20 June 2025.
お知らせ • Mar 26Pharmaron Beijing Co., Ltd. Proposes Final Dividend for the Financial Year Ended December 31, 2024Pharmaron Beijing Co., Ltd. proposed final dividend of RMB 2 per 10 shares for the financial year ended December 31, 2024.
お知らせ • Jun 21Pharmaron Beijing Co., Ltd. Announces Final Cash Dividend on A Shares for the Year 2023, Payable June 27, 2024Pharmaron Beijing Co., Ltd. announced final cash dividend/10 shares (tax included) of CNY 2.00000000 on A shares for the year 2023. Record date is June 26, 2024. Ex-date is June 27, 2023. Payment date is June 27, 2024.
お知らせ • Jun 08Pharmaron Beijing Co., Ltd. Approves Final Dividend for the Financial Year Ended December 31, 2023, Payable on July 26, 2024Pharmaron Beijing Co., Ltd. approved final dividend of RMB 2 per 10 shares for the financial year ended December 31, 2023. Ex-dividend date is on 27 June 2024. Record date is on 08 July 2024. Payment date is on 26 July 2024. Date of shareholders' approval is on 6 June 2024.
お知らせ • Apr 26+ 1 more updatePharmaron Beijing Co., Ltd. (SZSE:300759) announces an Equity Buyback for CNY 300 million worth of its shares.Pharmaron Beijing Co., Ltd. (SZSE:300759) announces a share repurchase program. Under the program, the company will repurchase up to CNY 300 million worth of class A shares. The shares will be repurchased at a price of not more than CNY 31 per share. The A Shares repurchased will all be cancelled and the Company’s registered capital will be reduced accordingly. The purpose of the program is to enhance investor’s confidence, and comprehensively taking into account the Company’s financial conditions, future development and reasonable valuation levels. The program will be funded out of the company's own funds. The program will be valid till 3 months.
お知らせ • Mar 27Pharmaron Beijing Co., Ltd. Proposes Final Dividend for the Financial Year Ended December 31, 2023Pharmaron Beijing Co., Ltd. proposed final dividend of RMB 2 per 10 shares for the financial year ended December 31, 2023.
お知らせ • May 22Pharmaron Beijing Co., Ltd., Annual General Meeting, Jun 12, 2026Pharmaron Beijing Co., Ltd., Annual General Meeting, Jun 12, 2026, at 13:30 China Standard Time. Location: juhui hall, 5/floor, block b, zhaolin plaza, no. 19 ronghua middle road, beijing economic & technological development area, daxing district, beijing., China
お知らせ • Apr 30Pharmaron Beijing Co., Ltd. Approves Changes in the Company's Accounting PoliciesThe board of directors of Pharmaron Beijing Co., Ltd. that the Board has resolved and approved the proposed changes in the Company's accounting policies. This announcement is made pursuant to the requirements of Rule 13.09(2) of the Listing Rules and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Cap. 571). On April 28, 2026, the audit committee of the Board (the "Audit Committee") reviewed and approved the Changes in Accounting Policies, the details of which are as follows: Overview of Changes in Accounting Policies (i) Nature, reasons and effective date of the Changes in Accounting Policies In December, 2025, the Ministry of Finance issued the Notice on the Issuance of Interpretation No. 19 of Accounting Standards for Business Enterprises (Cai Kuai [2025] No. 32) (hereinafter referred to as "Interpretation No. 19"), which stipulates the accounting treatments regarding (i) accounting treatment of indemnification assets in business combinations under non-common control, (ii) accounting treatment of disposing of capital reserve related to the acquisition of subsidiaries through business combinations under common control, (iii) derecognition of financial liabilities settled through electronic payment systems, (iv) assessment of contractual cash flow characteristics of financial assets and related disclosures, and (v) disclosures of equity instruments designated as measured at fair value through other comprehensive income. The Interpretation No. 19 shall take effect from January 1, 2026. In accordance with the Interpretation No. 19, the Company has adopted the above accounting standards for business enterprises and the related accounting policies commencing from the effective date specified therein. These Changes in Accounting Policies are made in accordance with the requirements of the unified national accounting system. (ii) Accounting policies adopted prior to the Changes in Accounting Policies Prior to the Changes in Accounting Policies, the Company adopted the Accounting Standards for Business Enterprises Basic Standards and various specific accounting standards, Application Guidelines for Accounting Standards for Business Enterprises, the interpretation announcements of the Accounting Standards for Business Enterprises and other relevant regulations issued by the Ministry of Finance. (iii) Accounting policies adopted after the Changes in Accounting Policies After the Changes in Accounting Policies, the Company will adopt the requirements of Interpretation No. 19. The unchanged remaining parts will continue to follow the Accounting Standards for Business Enterprises Basic Standards and various specific accounting standards, the Application Guidelines for Accounting Standards for Business Enterprises, the interpretation announcements of the Accounting Standards for Business Enterprises and other relevant regulations previously issued by the Ministry of Finance. II. Impacts of Changes in Accounting Policies on the Company These Changes in Accounting Policies are made by the Company in accordance with the relevant regulations and requirements of the Ministry of Finance, and are in compliance with relevant laws and regulations. The revised accounting policies objectively and fairly reflect the Company's financial position and operating results. The Changes in Accounting Policies do not involve retroactive adjustment of financial data for previous years, will have no material effect on the Company's financial position, operating results or cash flows, and do not prejudice the interests of the Company and all of its shareholders. The Change in Accounting Policies is a modification under the China Accounting Standards, and will not have any impact on the Company's audited consolidated financial statements prepared in accordance with IFRS Accounting Standards (which include all International Financial Reporting Standards, International Accounting Standards and Interpretations) as issued by the International Accounting Standards Board. III. Opinion of the Audit Committee of the Board The Audit Committee is of the opinion that the Changes in Accounting Policies are made by the Company in compliance with the requirements of the relevant documents issued by the Ministry of Finance and constitute changes in accounting policies as required by the unified national accounting system. The revised accounting policies objectively and fairly reflect the Company's financial position and operating results. The Changes in Accounting Policies do not involve retroactive adjustment of financial data for previous years and do not prejudice the interests of the Company and all of its shareholders. The Audit Committee unanimously approved the Changes in Accounting Policies. In accordance with the Rules Governing the Listing of Stocks on the ChiNext Board of the Shenzhen Stock Exchange and other applicable laws, regulations and departmental rules, the Changes in Accounting Policies are not required to be submitted to the Board or the 2025 AGM for approval.
お知らせ • Apr 29Pharmaron Beijing Co., Ltd. Announces Board ResignationsPharmaron Beijing Co., Ltd. announced that Mr. LI Jiaqing and Mr. YU Jian will not stand for re-election of the fourth session of the Board. Each of Mr. LI Jiaqing and Mr. YU Jian has confirmed that he has no disagreement with the Board and there is no matter that need to be brought to the attention of the Shareholders with regard to his resignation. As at the date of this announcement, neither Mr. LI Jiaqing nor Mr. YU Jian has any interest in the shares of the Company within the meaning of Part XV of the SFO nor any other matter which needs to be brought to the attention of the Shareholders. The Board would like to take this opportunity to express its appreciation and gratitude to Mr. LI Jiaqing and Mr. YU Jian for their valuable contribution made to the Company during their respective term of service.
お知らせ • Mar 31Pharmaron Beijing Co., Ltd. to Report Q1, 2026 Results on Apr 29, 2026Pharmaron Beijing Co., Ltd. announced that they will report Q1, 2026 results on Apr 29, 2026
お知らせ • Jan 22Pharmaron Beijing Co., Ltd. has completed a Follow-on Equity Offering in the amount of HKD 1.333618 billion.Pharmaron Beijing Co., Ltd. has completed a Follow-on Equity Offering in the amount of HKD 1.333618 billion. Security Name: H shares Security Type: Common Stock Securities Offered: 58,440,762 Price\Range: HKD 22.82 Transaction Features: Subsequent Direct Listing
お知らせ • Jan 15Pharmaron Beijing Co., Ltd. has filed a Follow-on Equity Offering in the amount of HKD 1.333618 billion.Pharmaron Beijing Co., Ltd. has filed a Follow-on Equity Offering in the amount of HKD 1.333618 billion. Security Name: H shares Security Type: Common Stock Securities Offered: 58,440,762 Price\Range: HKD 22.82 Transaction Features: Subsequent Direct Listing
お知らせ • Jan 14Pharmaron Beijing Co., Ltd. Provides Earnings Guidance for the Financial Year Ended December 31, 2025Pharmaron Beijing Co., Ltd. provided earnings guidance for the financial year ended December 31, 2025. For the period, the company expects the revenue in the range of RMB 13,871.6256 million to RMB 14,239.8989 million, growth compared with the same period of last year is 13% - 16%. Net profit attributable to owners of the parent is expected to be in the range of RMB 1,614.0157 million to RMB 1,685.7498 million, decrease compared with the same period of last year of 6% to 10%. Basic earnings per share is expected to be in the range of RMB 0.0.9160 to RMB 0.9567.
お知らせ • Dec 31Pharmaron Beijing Co., Ltd. to Report Fiscal Year 2025 Results on Mar 31, 2026Pharmaron Beijing Co., Ltd. announced that they will report fiscal year 2025 results on Mar 31, 2026
お知らせ • Oct 29Pharmaron Beijing Co., Ltd. (SZSE:300759) entered into a definitive Share Purchase Agreement to acquire 82.54% stake in Wuxi Biortus Biosciences Co. Ltd.Pharmaron Beijing Co., Ltd. (SZSE:300759) entered into a definitive Share Purchase Agreement to acquire 82.54% stake in Wuxi Biortus Biosciences Co. Ltd. on October 28, 2025. With this transaction, it will further enhance its service capabilities in protein science, biological assaying and compound screening, protein crystallization and structure analysis and structure-based drug design. The transaction is expected to close upon the satisfaction of customary closing conditions.
お知らせ • Sep 30Pharmaron Beijing Co., Ltd. to Report Q3, 2025 Results on Oct 29, 2025Pharmaron Beijing Co., Ltd. announced that they will report Q3, 2025 results on Oct 29, 2025
お知らせ • Jul 02Pharmaron Beijing Co., Ltd. to Report First Half, 2025 Results on Aug 22, 2025Pharmaron Beijing Co., Ltd. announced that they will report first half, 2025 results on Aug 22, 2025
お知らせ • Jun 20Pharmaron Beijing Co., Ltd. Approves Final Ordinary Dividend for Year Ended December 31, 2024, Payment Date Is 06 August 2025Pharmaron Beijing Co., Ltd. approved final ordinary dividend in cash for the year ended December 31, 2024 of RMB 2 per 10 share. Ex-dividend date is 04 July 2025 . Record date is 14 July 2025. Payment date is 06 August 2025. Date of shareholders' approval is 20 June 2025.
お知らせ • May 29Pharmaron Beijing Co., Ltd., Annual General Meeting, Jun 20, 2025Pharmaron Beijing Co., Ltd., Annual General Meeting, Jun 20, 2025, at 13:30 China Standard Time. Location: no. 1 meeting room,4th floor, grand skylight international hotel beijing, building 10, avic plaza, no. 15 ronghua south road, yizhuang economic and technological development, zone, daxing China
お知らせ • Apr 28Pharmaron Beijing Co., Ltd. Announces Resignation of Hu Baifeng as Non-Executive Director and A Member of the Strategy CommitteePharmaron Beijing Co., Ltd. announced that Mr. Hu Baifeng (Mr. Hu) has tendered a voluntary resignation from his position as a non-executive Director of the Company and a member of the strategy committee of the Board (the Strategy Committee). Following Mr. Hu's resignation, he has voluntarily agreed to continue to perform his duties as a non-executive Director and a member of the Strategy Committee until the proposed election of the new non-executive Director is resolved by the shareholders of the Company (the Shareholders) at the upcoming annual general meeting of the Company for the year 2024 (the 2024 AGM).
お知らせ • Mar 31Pharmaron Beijing Co., Ltd. to Report Q1, 2025 Results on Apr 28, 2025Pharmaron Beijing Co., Ltd. announced that they will report Q1, 2025 results on Apr 28, 2025
お知らせ • Mar 26Pharmaron Beijing Co., Ltd. Proposes Final Dividend for the Financial Year Ended December 31, 2024Pharmaron Beijing Co., Ltd. proposed final dividend of RMB 2 per 10 shares for the financial year ended December 31, 2024.
お知らせ • Dec 31Pharmaron Beijing Co., Ltd. to Report Fiscal Year 2024 Results on Mar 27, 2025Pharmaron Beijing Co., Ltd. announced that they will report fiscal year 2024 results on Mar 27, 2025
お知らせ • Sep 30Pharmaron Beijing Co., Ltd. to Report Q3, 2024 Results on Oct 30, 2024Pharmaron Beijing Co., Ltd. announced that they will report Q3, 2024 results on Oct 30, 2024
お知らせ • Jun 29Pharmaron Beijing Co., Ltd. to Report First Half, 2024 Results on Aug 28, 2024Pharmaron Beijing Co., Ltd. announced that they will report first half, 2024 results on Aug 28, 2024
お知らせ • Jun 22Johnson & Johnson (NYSE:JNJ) completed the acquisition of Proteologix, Inc. from Pharmaron Beijing Co., Ltd and other shareholders for approximately $850 million.Johnson & Johnson (NYSE:JNJ) entered into a definitive agreement to acquire Proteologix, Inc. from Pharmaron Beijing Co., Ltd and other shareholders for approximately $850 million and with potential for an additional milestone payment. on May 16, 2024. The transaction is subject to antitrust clearance and other customary closing conditions. The transaction is expected to close mid-year 2024. Centerview Partners LLC served as exclusive financial advisor, and Goodwin Procter as legal counsel to Proteologix on the transaction. The transaction has been approved by Pharmaron Beijing Co., Ltd's board.As of year ended 2023, Proteologix, Inc reported total assets of $31.04 million, total common equity of $30.73 million, EBIT of $5.74 million and net income of $5.74 million. Janet Xiao of Morrison & Foerster LLP acted as legal advisor to Proteologix, Inc.Johnson & Johnson (NYSE:JNJ) completed the acquisition of Proteologix, Inc. from Pharmaron Beijing Co., Ltd and other shareholders on June 21, 2024.
お知らせ • Jun 21Pharmaron Beijing Co., Ltd. Announces Final Cash Dividend on A Shares for the Year 2023, Payable June 27, 2024Pharmaron Beijing Co., Ltd. announced final cash dividend/10 shares (tax included) of CNY 2.00000000 on A shares for the year 2023. Record date is June 26, 2024. Ex-date is June 27, 2023. Payment date is June 27, 2024.
お知らせ • Jun 08Pharmaron Beijing Co., Ltd. Approves Final Dividend for the Financial Year Ended December 31, 2023, Payable on July 26, 2024Pharmaron Beijing Co., Ltd. approved final dividend of RMB 2 per 10 shares for the financial year ended December 31, 2023. Ex-dividend date is on 27 June 2024. Record date is on 08 July 2024. Payment date is on 26 July 2024. Date of shareholders' approval is on 6 June 2024.
お知らせ • May 16Pharmaron Beijing Co., Ltd., Annual General Meeting, Jun 06, 2024Pharmaron Beijing Co., Ltd., Annual General Meeting, Jun 06, 2024, at 13:30 China Standard Time. Location: paris hall, 3/f, pullman beijing south, no. 12 ronghua south road, beijing economic and technological development, area, daxing district, beijing China
お知らせ • Apr 26+ 1 more updatePharmaron Beijing Co., Ltd. (SZSE:300759) announces an Equity Buyback for CNY 300 million worth of its shares.Pharmaron Beijing Co., Ltd. (SZSE:300759) announces a share repurchase program. Under the program, the company will repurchase up to CNY 300 million worth of class A shares. The shares will be repurchased at a price of not more than CNY 31 per share. The A Shares repurchased will all be cancelled and the Company’s registered capital will be reduced accordingly. The purpose of the program is to enhance investor’s confidence, and comprehensively taking into account the Company’s financial conditions, future development and reasonable valuation levels. The program will be funded out of the company's own funds. The program will be valid till 3 months.
お知らせ • Mar 30Pharmaron Beijing Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024Pharmaron Beijing Co., Ltd. announced that they will report Q1, 2024 results on Apr 26, 2024
お知らせ • Mar 27Pharmaron Beijing Co., Ltd. Proposes Final Dividend for the Financial Year Ended December 31, 2023Pharmaron Beijing Co., Ltd. proposed final dividend of RMB 2 per 10 shares for the financial year ended December 31, 2023.
お知らせ • Jan 29Pharmaron Beijing Co., Ltd. Provides Earnings Guidance for the Financial Year Ended December 31, 2023Pharmaron Beijing Co., Ltd. provided earnings guidance for the financial year ended December 31, 2023. For the period, the company expects the revenue in the range of RMB 11,395.5799 million to RMB 11,703.5685 million. Growth compared with the same period of last year is 11% - 14%. Net profit attributable to owners of the parent is expected to be in the range of RMB 1,567.0488 million to RMB 1,635.7790 million. Growth compared with the same period of last year of 14% to 19%. Basic earnings per share is expected to be in the range of RMB 0.8841 to 0.9229.
お知らせ • Dec 29Pharmaron Beijing Co., Ltd. to Report Fiscal Year 2023 Results on Mar 28, 2024Pharmaron Beijing Co., Ltd. announced that they will report fiscal year 2023 results on Mar 28, 2024